Adenocarcinomas on the rise - Does it influence survival from oesophageal cancer?

Scandinavian Journal of Surgery

Volumn 98, Issue 4, 2009, Pages 214-220

  Goscinski, Mariusz A ^a   Larsen, S G ^a   Warloe, T ^a   Stoldt, S ^a   Nesland, J M ^a,b   Suo, Z H ^a,b   Giercksky, K E ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Barrett's oesophagus; Oesophageal adenocarcinoma; Oesophageal squamous cell carcinoma; Risk factors; Survival; Treatment

Indexed keywords

EID: 73649135335     PISSN: 14574969     EISSN: None     Source Type: Journal    
DOI: 10.1177/145749690909800404     Document Type: Article

References (30)

1. Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053
2. Murray L, Romero Y: Role of obesity in Barrett's esophagus and cancer. Surg Oncol Clin N Am 2009;18:439-452
3. Merry AH, Schouten LJ, Goldbohm RA et al: Body mass index, height and risk of adenocarcinoma of the oesophagus and gastric cardia: a prospective cohort study. Gut 2007;56:1503-1511
4. Lagergren J, Bergström R, Lindgren A et al: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831
5. Wu AH, Wan P, Bernstein L: A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinoma of the stomach and esophagus (United States). Cancer Causes Control 2001;12:721-732
6. Brown LM, Hoover R, Silverman D et al: Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol 2001; 153:114-122
7. Essilfie I, Hoff DA, Hatlebakk JG: Treatment of gastroesophageal reflux disease. Tidsskr Nor Laegeforen 2007;127:3082-4
8. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av øsofaguscancer (spiserørskreft) - Nasjonale faglige retningslinjer - Sosial- og helsedirektoratet http://www.shdir.no/vp/multimedia/archive/00021/Nasjonalt-handlingsp-21459a.pdf
9. International Statistical Classification of Diseases and Related Health Problems. 10th Revision Version for 2007. WHO, Geneva, Switzerland, 2007
10. Histological typing of gastric and esophageal tumors. In: WHO international histological classification of tumors. Springer-Verlag, Berlin, Germany, 1990
11. UICC: TNM Atlas, 5th Edition: An Illustrated Guide to the TNM/pTNM Classification of Malignant Tumours. Digestive System Tumours. Eds Ch. Wittekind, FL Greene, RVP Hutter, M Klimpfinger and LH Sobin. Springer-Verlag, Heidelberg, Germany, 2005, pp 74-83
12. Cancer in Norway 2006. Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway: Institute of population-based Cancer Research, Oslo, Norway, 2006, pp 22-3, 34-36
13. Corley DA, Buffler PA: Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database. Int J Epidemiol 2001;30:1415-1425
14. Powell J, McConkey CC, Gillison EW et al: Continuing rising trend in oesophageal adenocarcinoma. Int J Cancer 2002;102:422-427
15. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut 2005;54:1-5
16. Kroppsmasseindeks og vurdering av vekt. Nasjonalt folkehelseinstitutt http://www.fhi.no/eway/default.aspx?pid=233&trg=MainArea-5661&MainArea- 5661=5631:0:15,2690:1:0:0:::0:0
17. Stadig færre røyker daglig. Røyking i Norge. Statistisk sentralbyrå, Statistics Norway http://www.ssb.no/royk/arkiv/ art-2008-01-31-01.html
18. Rouvelas I, Zeng W, Lindblad M et al: Survival after surgery for oesophageal cancer: a population based study. Lancet Oncol 2005;6:864-870
19. Siewert JR, von Rahden BHA: Current status of esophageal cancer - West versus East: the European point of view. Esophagus 2004;1:147-159
20. Stein HJ, von Rahden BHA, Siewert JR: Survival after oesophagectomy for cancer of the oesophagus. Langenbecks Arch Surg 2005;390:280-285
21. Hofstetter W, Swisher SG, Correa AM et al: Treatment outcomes of resected esophageal cancer. Ann Surg 2002;236:376-384
22. 6th ed. Springer, New York, USA, 2002: pp 91-95
23. Hulscher JB, van Sandick JW, de Boer AG et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347:1662-1669
24. Cunningham D, Allum WH, Stenning SP et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20
25. Brørs O: Dosaging of proton pumps inhibitors. Tidsskr Nor Laegeforen 2006;126:2397-2399
26. Trondsen E, Bakken IJ, Skjeldestad FE: Anti-reflux surgery in Norway. Tidsskr Nor Laegeforen 2005;125:1990-1992
27. Vallböhmer D, Lenz HJ: Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006;19:425-432
28. Kuo KT, Chow KC, Wu YC: Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma. Ann Thorac Surg 2003;76:909-194
29. Goscinski MA, Suo Z, Flørenes VA, Vlatkovic et al: FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions. Ultrastruct Pathol 2008;32:89-96
30. Goscinski MA, Suo ZH, Nesland JM et al: Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China. Oncology 2008;75:49-59